Clinical and molecular characterisation of metastatic papillary thyroid cancer according to radioiodine therapy outcomes

Detalhes bibliográficos
Autor(a) principal: Simões-Pereira, Joana
Data de Publicação: 2023
Outros Autores: Saramago, Ana, Rodrigues, Ricardo, Pojo, Marta, Pires, Carolina, Horta, Mariana, López-Presa, Dolores, Rito, Miguel, Cabrera, Rafael, Ferreira, Teresa C., Leite, Valeriano, Cavaco, Branca M.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10362/161725
Resumo: Funding Information: This study was funded by iNOVA4Health Research Unit (LISBOA-01-0145-FEDER-007344; UID/Multi/00462; UIDB/04462/2020), a program co-funded by Fundação para a Ciência e Tecnologia/Ministério da Ciência e do Ensino Superior, Sociedade Portuguesa de Endocrinologia, Diabetes e Metabolismo (SPEDM), and Instituto Português de Oncologia de Lisboa Francisco Gentil (IPOLFG). J.S.-P. was supported by iNOVA4Health – UIDB/04462/2020. M.P. was granted by Liga Portuguesa Contra o Cancro, Núcleo Regional do Sul (LPCC-NRS). R.R. was granted with a PhD scholarship by iNOVA4Health Research Unit - UIDP/04462/2020; UI/BD/154256/2022. C.P. was granted with a PhD scholarship by FCT – 2020.07120.BD. Publisher Copyright: © 2023, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
id RCAP_05d6998eb1320715987caf9e24e9e37d
oai_identifier_str oai:run.unl.pt:10362/161725
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Clinical and molecular characterisation of metastatic papillary thyroid cancer according to radioiodine therapy outcomesAvidityMetastasisPapillary thyroid cancerRadioiodine therapyRAS genesTERT promoterEndocrinology, Diabetes and MetabolismEndocrinologySDG 3 - Good Health and Well-beingFunding Information: This study was funded by iNOVA4Health Research Unit (LISBOA-01-0145-FEDER-007344; UID/Multi/00462; UIDB/04462/2020), a program co-funded by Fundação para a Ciência e Tecnologia/Ministério da Ciência e do Ensino Superior, Sociedade Portuguesa de Endocrinologia, Diabetes e Metabolismo (SPEDM), and Instituto Português de Oncologia de Lisboa Francisco Gentil (IPOLFG). J.S.-P. was supported by iNOVA4Health – UIDB/04462/2020. M.P. was granted by Liga Portuguesa Contra o Cancro, Núcleo Regional do Sul (LPCC-NRS). R.R. was granted with a PhD scholarship by iNOVA4Health Research Unit - UIDP/04462/2020; UI/BD/154256/2022. C.P. was granted with a PhD scholarship by FCT – 2020.07120.BD. Publisher Copyright: © 2023, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.Purpose: Radioiodine (RAI) therapy remains the gold-standard approach for distant metastatic differentiated thyroid cancer (TC). The main objective of our work was to identify the clinical and molecular markers that may help to predict RAI avidity and RAI therapy response of metastatic lesions in a cohort of papillary thyroid cancer (PTC) patients. Methods: We performed a retrospective analysis of 122 PTC patients submitted to RAI therapy due to distant metastatic disease. We also analysed, through next-generation sequencing, a custom panel of 78 genes and rearrangements, in a smaller cohort of 31 metastatic PTC, with complete follow-up, available RAI therapy data, and existing tumour sample at our centre. Results: The most frequent outcome after RAI therapy was progression of disease in 59.0% of cases (n = 71), with median estimate progression-free survival of 30 months. RAI avidity was associated with PTC subtype, age and stimulated thyroglobulin at first RAI therapy for metastatic disease. The most frequently altered genes in the cohort of 31 PTC patients’ primary tumours were RAS isoforms (54.8%) and TERT promoter (TERTp) (51.6%). The presence of BRAF p.V600E or RET/PTC alterations was associated with lower avidity (p = 0.012). TERTp mutations were not associated with avidity (p = 1.000) but portended a tendency for a higher rate of progression (p = 0.063); similar results were obtained when RAS and TERTp mutations coexisted (p = 1.000 and p = 0.073, respectively). Conclusions: Early identification of molecular markers in primary tumours may help to predict RAI therapy avidity, the response of metastatic lesions and to select the patients that may benefit the most from other systemic therapies.NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)RUNSimões-Pereira, JoanaSaramago, AnaRodrigues, RicardoPojo, MartaPires, CarolinaHorta, MarianaLópez-Presa, DoloresRito, MiguelCabrera, RafaelFerreira, Teresa C.Leite, ValerianoCavaco, Branca M.2023-12-28T22:32:55Z20232023-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10362/161725eng1355-008XPURE: 79232375https://doi.org/10.1007/s12020-023-03633-yinfo:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2024-03-11T05:44:36Zoai:run.unl.pt:10362/161725Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T03:58:37.749410Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Clinical and molecular characterisation of metastatic papillary thyroid cancer according to radioiodine therapy outcomes
title Clinical and molecular characterisation of metastatic papillary thyroid cancer according to radioiodine therapy outcomes
spellingShingle Clinical and molecular characterisation of metastatic papillary thyroid cancer according to radioiodine therapy outcomes
Simões-Pereira, Joana
Avidity
Metastasis
Papillary thyroid cancer
Radioiodine therapy
RAS genes
TERT promoter
Endocrinology, Diabetes and Metabolism
Endocrinology
SDG 3 - Good Health and Well-being
title_short Clinical and molecular characterisation of metastatic papillary thyroid cancer according to radioiodine therapy outcomes
title_full Clinical and molecular characterisation of metastatic papillary thyroid cancer according to radioiodine therapy outcomes
title_fullStr Clinical and molecular characterisation of metastatic papillary thyroid cancer according to radioiodine therapy outcomes
title_full_unstemmed Clinical and molecular characterisation of metastatic papillary thyroid cancer according to radioiodine therapy outcomes
title_sort Clinical and molecular characterisation of metastatic papillary thyroid cancer according to radioiodine therapy outcomes
author Simões-Pereira, Joana
author_facet Simões-Pereira, Joana
Saramago, Ana
Rodrigues, Ricardo
Pojo, Marta
Pires, Carolina
Horta, Mariana
López-Presa, Dolores
Rito, Miguel
Cabrera, Rafael
Ferreira, Teresa C.
Leite, Valeriano
Cavaco, Branca M.
author_role author
author2 Saramago, Ana
Rodrigues, Ricardo
Pojo, Marta
Pires, Carolina
Horta, Mariana
López-Presa, Dolores
Rito, Miguel
Cabrera, Rafael
Ferreira, Teresa C.
Leite, Valeriano
Cavaco, Branca M.
author2_role author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)
RUN
dc.contributor.author.fl_str_mv Simões-Pereira, Joana
Saramago, Ana
Rodrigues, Ricardo
Pojo, Marta
Pires, Carolina
Horta, Mariana
López-Presa, Dolores
Rito, Miguel
Cabrera, Rafael
Ferreira, Teresa C.
Leite, Valeriano
Cavaco, Branca M.
dc.subject.por.fl_str_mv Avidity
Metastasis
Papillary thyroid cancer
Radioiodine therapy
RAS genes
TERT promoter
Endocrinology, Diabetes and Metabolism
Endocrinology
SDG 3 - Good Health and Well-being
topic Avidity
Metastasis
Papillary thyroid cancer
Radioiodine therapy
RAS genes
TERT promoter
Endocrinology, Diabetes and Metabolism
Endocrinology
SDG 3 - Good Health and Well-being
description Funding Information: This study was funded by iNOVA4Health Research Unit (LISBOA-01-0145-FEDER-007344; UID/Multi/00462; UIDB/04462/2020), a program co-funded by Fundação para a Ciência e Tecnologia/Ministério da Ciência e do Ensino Superior, Sociedade Portuguesa de Endocrinologia, Diabetes e Metabolismo (SPEDM), and Instituto Português de Oncologia de Lisboa Francisco Gentil (IPOLFG). J.S.-P. was supported by iNOVA4Health – UIDB/04462/2020. M.P. was granted by Liga Portuguesa Contra o Cancro, Núcleo Regional do Sul (LPCC-NRS). R.R. was granted with a PhD scholarship by iNOVA4Health Research Unit - UIDP/04462/2020; UI/BD/154256/2022. C.P. was granted with a PhD scholarship by FCT – 2020.07120.BD. Publisher Copyright: © 2023, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
publishDate 2023
dc.date.none.fl_str_mv 2023-12-28T22:32:55Z
2023
2023-01-01T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10362/161725
url http://hdl.handle.net/10362/161725
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 1355-008X
PURE: 79232375
https://doi.org/10.1007/s12020-023-03633-y
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799138167362682880

Registros relacionados